We have made considerable progress with Her2 targeting, especially in the first line, our Dr. Jaffer Ajani shared at #AACR26. Zanidatamab...

返回会议原文

返回会议

UT MD Anderson· @UTMDAnderson · X·2026-04-20 05:00· 2026-04-20评分60

zanidatamab

解读

ADC 下一代 — 载荷创新

zanidatamab 新辅助 · 无化疗 pCR 30%，HER2 下调 56%

正文 · 原文

We have made considerable progress with Her2 targeting, especially in the first line, our Dr. Jaffer Ajani shared at #AACR26. Zanidatamab/tislelizumab/chemo may be given to Her2 positive gastroesophageal adenocarcinoma patients, regardless of PDL-1 status. #EndCancer

热度 17 · 13 赞 · 0 回复 · 4 转发

会议摘要

4542按药名 zanidatamab 对上

Zanidatamab modulates multiple pathways involved in tumor growth and survival and is efficacious post T-DXd

Ankur Karmokar, Emanuele Loro, Al Hassan Kyakulaga, Desmond Lau, Nina Weisser, Genevieve Desjardins, Prajwal Raghunatha, Edwin Clark, Robin Humphreys, Kedar S. Vaidya

读摘要原文 →

CT012按药名 zanidatamab 对上

A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study

Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam

读摘要原文 →

CT209NCT06695845按药名 zanidatamab 对上

DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2-overexpressing solid tumors

Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam

读摘要原文 →

来源：UT MD Anderson · x.com